Synthesis of an Ammended Analogue of Delavirdine

The efficacy of delavirdine is lower than other FDA approved NNRTIs, therefore, the US department of health and Human Services has recommended its use not as a part of initial therapy but in combination with other drugs. To circumvent this therapeutic difficulty of delavirdine, we amended its structure to develop a novel analogue by replacing its less active indole fragment with a more active anti-HIV prone isatin's Mannich bases. The molecular assemblage of delavirdine was concurrently also altered by rearranging its vital fragments to allow it to emerge with altogether a different molecular setting.

Autorentext

Dr.Rachna Mishra is Ph.D in Chemistry from Banasthali University, Jaipur - India. She worked on Synthesis of Delavirdine analouges in her research time. She has been engaged in chemistry teaching at institutions in India. Born at Moth, Jhansi - India, She has a great interest in Chemistry and chemical analysis for drugs."Chemistry is Life".